The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)
Status:
Completed
Trial end date:
2013-10-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Boceprevir (BOC, SCH 503034, MK-3034) in
combination with Peginterferon Alfa 2-b (PEG) plus Ribavirin (RBV) [PEG+RBV=PR] is effective
in the treatment of chronic hepatitis C (CHC) genotype 1 among the Russian population. The
primary hypothesis is that the percentage of participants achieving sustained virologic
response in the BOC + PR group is superior to that in the Placebo (PBO) + PR group.